Floatz logo

sta363

Low Back Pain

Stayble TherapeuticsPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Low Back Pain cohort.

Asset / SponsorPhaseRating
Oxycodone
Brigham and Women's Hospital
Phase 4BBB
FENTANYL
Balnear and Rehabilitation Sanatorium Techirghiol
Phase 4BBB
Tapentadol
Grünenthal GmbH
Phase 4BBB
Buprenorphine
BioDelivery Sciences International
Phase 4BBB
17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE
Grünenthal GmbH
Phase 4BBB

View all 50 →

Same molecule, other indications

sta363 is also rated in:

intervertebral disk degenerative disorderDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →